Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 3Solid Tumours 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Lymphoma 1Long QT Syndrome 1Hot Flashes 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

zopiclone 1fezolinetant 1Tamoxifen 1N,N'-(1,4-phenylenebis(methylene))dipyrimidin-2-amine 1Moxifloxacin 1Mannose-Binding Lectin 1Esomeprazole 1Dabigatran 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hot Flashes × Moxifloxacin × Clear all
NCT05481528 2023-05-09

A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants

Bayer

Phase 1 Completed
51 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 1, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡